AIRLINK 80.30 Increased By ▲ 0.89 (1.12%)
BOP 5.28 Decreased By ▼ -0.05 (-0.94%)
CNERGY 4.37 Decreased By ▼ -0.01 (-0.23%)
DFML 34.83 Increased By ▲ 1.64 (4.94%)
DGKC 76.40 Decreased By ▼ -0.47 (-0.61%)
FCCL 20.53 No Change ▼ 0.00 (0%)
FFBL 31.65 Increased By ▲ 0.25 (0.8%)
FFL 9.75 Decreased By ▼ -0.10 (-1.02%)
GGL 10.20 Decreased By ▼ -0.05 (-0.49%)
HBL 117.35 Decreased By ▼ -0.58 (-0.49%)
HUBC 134.45 Increased By ▲ 0.35 (0.26%)
HUMNL 7.00 No Change ▼ 0.00 (0%)
KEL 4.58 Decreased By ▼ -0.09 (-1.93%)
KOSM 4.71 Decreased By ▼ -0.03 (-0.63%)
MLCF 37.25 Decreased By ▼ -0.19 (-0.51%)
OGDC 136.20 Decreased By ▼ -0.50 (-0.37%)
PAEL 23.07 Decreased By ▼ -0.08 (-0.35%)
PIAA 27.01 Increased By ▲ 0.46 (1.73%)
PIBTL 6.99 Decreased By ▼ -0.01 (-0.14%)
PPL 113.50 Decreased By ▼ -0.25 (-0.22%)
PRL 27.33 Decreased By ▼ -0.19 (-0.69%)
PTC 14.80 Increased By ▲ 0.05 (0.34%)
SEARL 57.05 Decreased By ▼ -0.15 (-0.26%)
SNGP 67.00 Decreased By ▼ -0.50 (-0.74%)
SSGC 11.01 Decreased By ▼ -0.08 (-0.72%)
TELE 9.29 Increased By ▲ 0.06 (0.65%)
TPLP 11.55 Decreased By ▼ -0.01 (-0.09%)
TRG 72.06 Decreased By ▼ -0.04 (-0.06%)
UNITY 25.57 Increased By ▲ 0.75 (3.02%)
WTL 1.37 Decreased By ▼ -0.03 (-2.14%)
BR100 7,542 Increased By 15.9 (0.21%)
BR30 24,619 Decreased By -30.2 (-0.12%)
KSE100 72,086 Increased By 114.4 (0.16%)
KSE30 23,780 Increased By 31.4 (0.13%)

Joe Biden

Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver
Markets

Global pharma shares sink as Biden backs COVID-19 vaccine IP waiver

  • "The production of mRNA vaccines is not just about intellectual property. A lot of other things are in play, such as manufacturing know-how and capacity. Other companies or countries are unlikely to produce mRNA shots quickly," he said.
  • Several pharmaceutical analysts said IP waivers may on the surface help a world facing a pandemic, but manufacturing the vaccines was a barrier.
Published 06 May, 2021 08:28pm
US backs plan to waive Covid-19 vaccine patents
World

US backs plan to waive Covid-19 vaccine patents

  • But that notion has been fiercely opposed by pharmaceutical giants and their host countries, which insist the patents are not the main roadblocks to scaling up production, and warned the move could hamper innovation.
Published 06 May, 2021 10:50am